Revenue and net results declined year-over-year, with continued negative operating results. Key milestones included progress in clinical pilot studies and a successful rights issue, supporting ongoing R&D and product industrialization.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.